Business description: Abpro Corporation

Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).

Other Biotechnology & Medical Research

Change 5-day change 1-year change 3-year change Capi.($)
+4.16%+3.42%+49.37%+94.17% 74.31B
-0.37%-3.81%+19.75%+78.12% 56.95B
+1.63%-1.61%+3.83%+36.89% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.69%+8.41%+38.10%+32.72% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.65%-0.15%+54.61%+128.69% 43.73B
Weighted average by Cap. +1.78%-0.46%+58.44%+137.19%
  1. Stock Market
  2. Stocks
  3. ABPO Stock
  4. Stock
  5. Company Abpro Corporation